388 related articles for article (PubMed ID: 33468562)
1. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
[TBL] [Abstract][Full Text] [Related]
2. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G
Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441
[TBL] [Abstract][Full Text] [Related]
4. Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling.
James AM; Hsu HT; Dongre P; Uzel G; Mace EM; Banerjee PP; Orange JS
Blood; 2013 Apr; 121(14):2627-37. PubMed ID: 23380740
[TBL] [Abstract][Full Text] [Related]
5. Fc receptor stimulation of phosphatidylinositol 3-kinase in natural killer cells is associated with protein kinase C-independent granule release and cell-mediated cytotoxicity.
Bonnema JD; Karnitz LM; Schoon RA; Abraham RT; Leibson PJ
J Exp Med; 1994 Oct; 180(4):1427-35. PubMed ID: 7931075
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
7. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
9. Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases.
Trotta R; Puorro KA; Paroli M; Azzoni L; Abebe B; Eisenlohr LC; Perussia B
J Immunol; 1998 Dec; 161(12):6648-56. PubMed ID: 9862693
[TBL] [Abstract][Full Text] [Related]
10. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.
Uherek C; Tonn T; Uherek B; Becker S; Schnierle B; Klingemann HG; Wels W
Blood; 2002 Aug; 100(4):1265-73. PubMed ID: 12149207
[TBL] [Abstract][Full Text] [Related]
11. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
14. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
15. Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1.
Darwich A; Silvestri A; Benmebarek MR; Mouriès J; Cadilha B; Melacarne A; Morelli L; Supino D; Taleb A; Obeck H; Sustmann C; Losurdo A; Masci G; Curigliano G; Kobold S; Penna G; Rescigno M
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824159
[TBL] [Abstract][Full Text] [Related]
16. JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity.
Li C; Ge B; Nicotra M; Stern JN; Kopcow HD; Chen X; Strominger JL
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3017-22. PubMed ID: 18287025
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression.
Masu T; Atsukawa M; Nakatsuka K; Shimizu M; Miura D; Arai T; Harimoto H; Kondo C; Kaneko K; Futagami S; Kawamoto C; Takahashi H; Iwakiri K
PLoS One; 2018; 13(12):e0200664. PubMed ID: 30596643
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
19. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
20. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
